[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Enliven Therapeutics Inc (ELVN)

Enliven Therapeutics Inc (ELVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,746,815
  • Shares Outstanding, K 60,905
  • Annual Sales, $ 0 K
  • Annual Income, $ -103,690 K
  • EBIT $ -116 M
  • EBITDA $ -116 M
  • 60-Month Beta 0.29
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.03

Options Overview Details

View History
  • Implied Volatility 66.11% (-4.82%)
  • Historical Volatility 73.06%
  • IV Percentile 1%
  • IV Rank 18.08%
  • IV High 238.27% on 01/07/26
  • IV Low 28.13% on 09/09/25
  • Expected Move (DTE 28) 2.31 (5.13%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 1,047
  • Volume Avg (30-Day) 1,677
  • Put/Call OI Ratio 2.05
  • Today's Open Interest 30,274
  • Open Int (30-Day) 22,415
  • Expected Range 42.79 to 47.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.42
  • Number of Estimates 2
  • High Estimate $-0.41
  • Low Estimate $-0.43
  • Prior Year $-0.49
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.45 +34.83%
on 06/08/26
47.36 -4.77%
on 06/12/26
+5.47 (+13.80%)
since 05/18/26
3-Month
26.72 +68.79%
on 03/19/26
48.53 -7.07%
on 04/17/26
+17.85 (+65.50%)
since 03/18/26
52-Week
14.78 +205.04%
on 01/06/26
48.53 -7.07%
on 04/17/26
+23.53 (+109.09%)
since 06/18/25

Most Recent Stories

More News
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

BURLINGAME, Calif. , June 15, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development...

ELVN : 45.10 (+0.53%)
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

BURLINGAME, Calif. , June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development...

ELVN : 45.10 (+0.53%)
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

BURLINGAME, Calif. , June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development...

ELVN : 45.10 (+0.53%)
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components

61% overall MMR and 48% MMR achievement by 24 weeks in the 80 mg QD Phase 1b cohort

ELVN : 45.10 (+0.53%)
Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress

Enliven will host a   webcast conference call   on   June   11,   at   8:30   a.m.   ET

ELVN : 45.10 (+0.53%)
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML

Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated 80 mg QD Phase 1b cohort

ELVN : 45.10 (+0.53%)
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

Phase 1 data update for ELVN-001 expected mid-2026

ELVN : 45.10 (+0.53%)
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

BOULDER, Colo. , Feb. 25, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development...

ELVN : 45.10 (+0.53%)
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones

Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts

ELVN : 45.10 (+0.53%)
Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development

Scott Garland, a seasoned biopharma executive with a strong track record of leading successful companies and drug launches, joins Enliven's Board of Directors

ELVN : 45.10 (+0.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Enliven Therapeutics Inc. is a clinical-stage precision oncology company focused on the discovery and development of small molecule kinase inhibitors. The Company's lead product candidate includes ELVN-001 and ELVN-002. Enliven Therapeutics Inc., formerly known as Imara Inc., is based in Boulder, CO....

See More

Key Turning Points

3rd Resistance Point 47.31
2nd Resistance Point 46.51
1st Resistance Point 45.81
Last Price 45.10
1st Support Level 44.31
2nd Support Level 43.51
3rd Support Level 42.81

See More

52-Week High 48.53
Last Price 45.10
Fibonacci 61.8% 35.64
Fibonacci 50% 31.66
Fibonacci 38.2% 27.68
52-Week Low 14.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.